Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Sexually transmitted disease

Lancet study reveals the first vaccine to show protection against gonorrhoea

The study’s findings could inform future vaccine development for both the meningococcal and gonorrhoea vaccines, its lead author claims.

Micrograph of Neisseria gonorrhoeae

Source: Centers for Disease Control and Prevention / Joe Miller

The author of the study confirmed that it was the first time that a vaccine showed any protection against gonorrhoea (micrograph pictured).

Exposure to the meningococcal group B vaccine is associated with a reduced likelihood of contracting gonorrhoea, according to the findings of a large study published in The Lancet[1].

The study, carried out during a mass vaccination campaign in New Zealand, involved more than 14,000 people. 

Dr Helen Petousis-Harris, University of Auckland, New Zealand, and lead author of the study, said: “This is the first time a vaccine has shown any protection against gonorrhoea. Our findings could inform future vaccine development for both the meningococcal and gonorrhoea vaccines.”

If the effect is confirmed in other available and similar meningococcal group B vaccines, researchers who carried out the study say that administering the vaccine in adolescence could result in significant declines in gonorrhoea, which has increasingly become drug resistant. The vaccine may even help to reduce rates of infection. 

Despite the two diseases — Neisseria gonorrhoeae and Neisseria meningitides— being very different in terms of symptoms and how it is transmitted, there is an 80–90% genetic match, which could provide a means of cross-protection.

In New Zealand, approximately one million people (81% of the population under 20 years) received the MeNZB vaccine — an outer membrane vesicle (OMV) meningococcal group B vaccine — during a mass immunisation programme in 2004–2006. This provided researchers with an opportunity to test the idea of cross-protection. 

They used data for all people aged 15-30 who had been diagnosed with gonorrhoea or chlamydia, or both, at 11 sexual health clinics, who were eligible to receive the MeNZB vaccine during the 2004–2006 vaccination programme.

A total of 14,730 cases and controls were included in the analysis (1,241 cases of gonorrhoea; 12,487 cases of chlamydia; 1,002 cases of co-infection). Vaccinated individuals were less likely to have gonorrhoea than controls (41% vs 51%). Researchers concluded that for those people who had previously received the MeNZB vaccine there was a reduced incidence of gonorrhoea by approximately 31%. 

MeNZB was developed to control a meningitis epidemic and is no longer available, but the OMV antigens thought to provoke the immune response to gonorrhoea have been included in the more recently developed 4CMenB vaccine, available in many countries. The authors say more research is now needed.

The study follows a warning from the World Health Organization (WHO) that untreatable strains of gonorrhoea are on the rise. Gonorrhoea is the second most common bacterial sexually transmitted infection (STI) in the UK after chlamydia, with almost 35,000 cases reported in England in 2014.

The WHO estimates that 78 million people worldwide contract the disease each year, with most cases affecting people under the age of 25.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203162

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £42.00Buy now
  • Pharmacy Case Studies

    Pharmacy Case Studies

    Understand the application of therapeutics in clinical practice with Pharmacy Case Studies. This book helps you to demonstrate the knowledge gained during your studies.

    £32.00Buy now
  • Integrated Pharmacy Case Studies

    Integrated Pharmacy Case Studies

    Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.

    £42.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £52.00Buy now
  • Introduction to Pharmaceutical Calculations

    Introduction to Pharmaceutical Calculations

    Introduction to Pharmaceutical Calculations is an essential study aid for pharmacy students. The book contains worked examples and sample questions and answers.

    £32.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £42.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Micrograph of Neisseria gonorrhoeae

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.